NCT00011986 · OUTCOME

Number of Participants With Observed Adverse Effects (Grade 3 and Above) Assessed by Common Toxicity Criteria Version 2.0

Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer · Source last updated 2019-04-16

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: COUNT_OF_PARTICIPANTS
Unit: Participants
Interval / dispersion: Not reported
Time frame: Up to 9 years

Analysis population: Eligible and treated participants

Groups in this outcome

Grade 3 and Above on ToxicityCarbo/Taxol

Carboplatin AUC 6 IV on day 1 plus Paclitaxel 175 mg/m2 IV on day 1 x 8 cycles

Grade 3 and Above on Carbo/Taxol/Gemcitabine

Carboplatin AUC 5 IV on day 1 plus Paclitaxel 175 mg/m2 IV on day 1 x 8 cycles plus Gemcitabine 800 mg/m2/dIV on days 1 and 8 x 8 cycles

Grade 3 and Above on Carbo/Taxol/Doxil

Carboplatin AUC 5 IV on day 1 plus Paclitaxel 175 mg/m2 IV on day 1 x 8 cycles plus Doxil 30 mg/m2 IV every other cycle on day 1 x 8 cycles

Grade 3 and Above on Carbo/Topotecan - Carbo/Taxol

Topotecan 1.25 mg/m2/dIV days 1-3 plus Carboplatin AUC 5 IV on day 3 plus x 4 cycles followed by Carboplatin AUC 6 IV on day 1 plus Paclitaxel 175 mg/m2 IV on day 1 x 4 cycles

Grade 3 and Above on Carbo/Gemcitabine - Carbo/Taxol

Gemcitabine 1000 mg/m2/dIV on days 1 and 8 plus Carboplatin AUC 6 IV on day 8 plus x 4 cycles followed by Carboplatin AUC 6 IV on day 1 plus Paclitaxel 175 mg/m2 IV on day 1 x 4 cycles

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Grade 3 and Above on ToxicityCarbo/Taxol	862
Grade 3 and Above on Carbo/Taxol/Gemcitabine	860
Grade 3 and Above on Carbo/Taxol/Doxil	854
Grade 3 and Above on Carbo/Topotecan - Carbo/Taxol	846
Grade 3 and Above on Carbo/Gemcitabine - Carbo/Taxol	851

Reported measurements

Leukopenia

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Grade 3 and Above on ToxicityCarbo/Taxol	438	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Taxol/Gemcitabine	686	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Taxol/Doxil	595	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Topotecan - Carbo/Taxol	476	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Gemcitabine - Carbo/Taxol	513	Not reported	Not reported	Not reported	Not reported

Neutropenia

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Grade 3 and Above on ToxicityCarbo/Taxol	749	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Taxol/Gemcitabine	798	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Taxol/Doxil	782	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Topotecan - Carbo/Taxol	779	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Gemcitabine - Carbo/Taxol	761	Not reported	Not reported	Not reported	Not reported

Thrombocytopenia

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Grade 3 and Above on ToxicityCarbo/Taxol	193	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Taxol/Gemcitabine	520	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Taxol/Doxil	320	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Topotecan - Carbo/Taxol	303	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Gemcitabine - Carbo/Taxol	486	Not reported	Not reported	Not reported	Not reported

Anemia

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Grade 3 and Above on ToxicityCarbo/Taxol	102	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Taxol/Gemcitabine	196	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Taxol/Doxil	160	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Topotecan - Carbo/Taxol	167	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Gemcitabine - Carbo/Taxol	203	Not reported	Not reported	Not reported	Not reported

Other Hematologic

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Grade 3 and Above on ToxicityCarbo/Taxol	156	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Taxol/Gemcitabine	338	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Taxol/Doxil	244	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Topotecan - Carbo/Taxol	246	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Gemcitabine - Carbo/Taxol	315	Not reported	Not reported	Not reported	Not reported

Allergy

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Grade 3 and Above on ToxicityCarbo/Taxol	38	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Taxol/Gemcitabine	20	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Taxol/Doxil	28	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Topotecan - Carbo/Taxol	21	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Gemcitabine - Carbo/Taxol	26	Not reported	Not reported	Not reported	Not reported

Auditory

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Grade 3 and Above on ToxicityCarbo/Taxol	5	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Taxol/Gemcitabine	2	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Taxol/Doxil	3	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Topotecan - Carbo/Taxol	2	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Gemcitabine - Carbo/Taxol	1	Not reported	Not reported	Not reported	Not reported

Cardiovascular

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Grade 3 and Above on ToxicityCarbo/Taxol	20	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Taxol/Gemcitabine	36	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Taxol/Doxil	34	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Topotecan - Carbo/Taxol	17	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Gemcitabine - Carbo/Taxol	23	Not reported	Not reported	Not reported	Not reported

Coagulation

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Grade 3 and Above on ToxicityCarbo/Taxol	5	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Taxol/Gemcitabine	10	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Taxol/Doxil	4	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Topotecan - Carbo/Taxol	9	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Gemcitabine - Carbo/Taxol	7	Not reported	Not reported	Not reported	Not reported

Constitutional

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Grade 3 and Above on ToxicityCarbo/Taxol	54	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Taxol/Gemcitabine	96	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Taxol/Doxil	84	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Topotecan - Carbo/Taxol	73	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Gemcitabine - Carbo/Taxol	57	Not reported	Not reported	Not reported	Not reported

Dermatologic

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Grade 3 and Above on ToxicityCarbo/Taxol	13	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Taxol/Gemcitabine	6	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Taxol/Doxil	11	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Topotecan - Carbo/Taxol	6	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Gemcitabine - Carbo/Taxol	8	Not reported	Not reported	Not reported	Not reported

Endocrine

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Grade 3 and Above on ToxicityCarbo/Taxol	0	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Taxol/Gemcitabine	4	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Taxol/Doxil	2	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Topotecan - Carbo/Taxol	1	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Gemcitabine - Carbo/Taxol	1	Not reported	Not reported	Not reported	Not reported

Gastrointestinal

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Grade 3 and Above on ToxicityCarbo/Taxol	90	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Taxol/Gemcitabine	145	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Taxol/Doxil	124	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Topotecan - Carbo/Taxol	105	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Gemcitabine - Carbo/Taxol	92	Not reported	Not reported	Not reported	Not reported

Genitourinary/Renal

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Grade 3 and Above on ToxicityCarbo/Taxol	9	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Taxol/Gemcitabine	8	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Taxol/Doxil	13	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Topotecan - Carbo/Taxol	6	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Gemcitabine - Carbo/Taxol	9	Not reported	Not reported	Not reported	Not reported

Hemorrhage

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Grade 3 and Above on ToxicityCarbo/Taxol	8	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Taxol/Gemcitabine	29	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Taxol/Doxil	20	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Topotecan - Carbo/Taxol	8	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Gemcitabine - Carbo/Taxol	30	Not reported	Not reported	Not reported	Not reported

Hepatic

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Grade 3 and Above on ToxicityCarbo/Taxol	13	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Taxol/Gemcitabine	32	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Taxol/Doxil	11	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Topotecan - Carbo/Taxol	13	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Gemcitabine - Carbo/Taxol	25	Not reported	Not reported	Not reported	Not reported

Infection/Fever

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Grade 3 and Above on ToxicityCarbo/Taxol	76	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Taxol/Gemcitabine	138	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Taxol/Doxil	134	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Topotecan - Carbo/Taxol	84	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Gemcitabine - Carbo/Taxol	82	Not reported	Not reported	Not reported	Not reported

Metabolic

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Grade 3 and Above on ToxicityCarbo/Taxol	61	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Taxol/Gemcitabine	55	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Taxol/Doxil	55	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Topotecan - Carbo/Taxol	37	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Gemcitabine - Carbo/Taxol	45	Not reported	Not reported	Not reported	Not reported

Musculoskeletal

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Grade 3 and Above on ToxicityCarbo/Taxol	7	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Taxol/Gemcitabine	18	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Taxol/Doxil	13	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Topotecan - Carbo/Taxol	8	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Gemcitabine - Carbo/Taxol	10	Not reported	Not reported	Not reported	Not reported

Neurologic

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Grade 3 and Above on ToxicityCarbo/Taxol	34	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Taxol/Gemcitabine	47	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Taxol/Doxil	43	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Topotecan - Carbo/Taxol	28	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Gemcitabine - Carbo/Taxol	35	Not reported	Not reported	Not reported	Not reported

Peripheral Neurologic

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Grade 3 and Above on ToxicityCarbo/Taxol	45	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Taxol/Gemcitabine	59	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Taxol/Doxil	45	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Topotecan - Carbo/Taxol	35	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Gemcitabine - Carbo/Taxol	24	Not reported	Not reported	Not reported	Not reported

Ocular/Visual

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Grade 3 and Above on ToxicityCarbo/Taxol	1	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Taxol/Gemcitabine	3	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Taxol/Doxil	1	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Topotecan - Carbo/Taxol	3	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Gemcitabine - Carbo/Taxol	3	Not reported	Not reported	Not reported	Not reported

Pain

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Grade 3 and Above on ToxicityCarbo/Taxol	53	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Taxol/Gemcitabine	75	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Taxol/Doxil	75	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Topotecan - Carbo/Taxol	66	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Gemcitabine - Carbo/Taxol	52	Not reported	Not reported	Not reported	Not reported

Pulmonary

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Grade 3 and Above on ToxicityCarbo/Taxol	19	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Taxol/Gemcitabine	37	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Taxol/Doxil	39	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Topotecan - Carbo/Taxol	21	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Gemcitabine - Carbo/Taxol	37	Not reported	Not reported	Not reported	Not reported

Sexual

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Grade 3 and Above on ToxicityCarbo/Taxol	0	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Taxol/Gemcitabine	0	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Taxol/Doxil	1	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Topotecan - Carbo/Taxol	1	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Gemcitabine - Carbo/Taxol	0	Not reported	Not reported	Not reported	Not reported

Second Primary

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Grade 3 and Above on ToxicityCarbo/Taxol	34	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Taxol/Gemcitabine	66	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Taxol/Doxil	51	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Topotecan - Carbo/Taxol	41	Not reported	Not reported	Not reported	Not reported
Grade 3 and Above on Carbo/Gemcitabine - Carbo/Taxol	57	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
438
group Id
OG001
value
686
group Id
OG002
value
595
group Id
OG003
value
476
group Id
OG004
value
513
title
Leukopenia
categories
measurements
group Id
OG000
value
749
group Id
OG001
value
798
group Id
OG002
value
782
group Id
OG003
value
779
group Id
OG004
value
761
title
Neutropenia
categories
measurements
group Id
OG000
value
193
group Id
OG001
value
520
group Id
OG002
value
320
group Id
OG003
value
303
group Id
OG004
value
486
title
Thrombocytopenia
categories
measurements
group Id
OG000
value
102
group Id
OG001
value
196
group Id
OG002
value
160
group Id
OG003
value
167
group Id
OG004
value
203
title
Anemia
categories
measurements
group Id
OG000
value
156
group Id
OG001
value
338
group Id
OG002
value
244
group Id
OG003
value
246
group Id
OG004
value
315
title
Other Hematologic
categories
measurements
group Id
OG000
value
38
group Id
OG001
value
20
group Id
OG002
value
28
group Id
OG003
value
21
group Id
OG004
value
26
title
Allergy
categories
measurements
group Id
OG000
value
5
group Id
OG001
value
2
group Id
OG002
value
3
group Id
OG003
value
2
group Id
OG004
value
1
title
Auditory
categories
measurements
group Id
OG000
value
20
group Id
OG001
value
36
group Id
OG002
value
34
group Id
OG003
value
17
group Id
OG004
value
23
title
Cardiovascular
categories
measurements
group Id
OG000
value
5
group Id
OG001
value
10
group Id
OG002
value
4
group Id
OG003
value
9
group Id
OG004
value
7
title
Coagulation
categories
measurements
group Id
OG000
value
54
group Id
OG001
value
96
group Id
OG002
value
84
group Id
OG003
value
73
group Id
OG004
value
57
title
Constitutional
categories
measurements
group Id
OG000
value
13
group Id
OG001
value
6
group Id
OG002
value
11
group Id
OG003
value
6
group Id
OG004
value
8
title
Dermatologic
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
4
group Id
OG002
value
2
group Id
OG003
value
1
group Id
OG004
value
1
title
Endocrine

denoms

counts
group Id
OG000
value
862
group Id
OG001
value
860
group Id
OG002
value
854
group Id
OG003
value
846
group Id
OG004
value
851
units
Participants

groups

description
Carboplatin AUC 6 IV on day 1 plus Paclitaxel 175 mg/m2 IV on day 1 x 8 cycles
id
OG000
title
Grade 3 and Above on ToxicityCarbo/Taxol
description
Carboplatin AUC 5 IV on day 1 plus Paclitaxel 175 mg/m2 IV on day 1 x 8 cycles plus Gemcitabine 800 mg/m2/dIV on days 1 and 8 x 8 cycles
id
OG001
title
Grade 3 and Above on Carbo/Taxol/Gemcitabine
description
Carboplatin AUC 5 IV on day 1 plus Paclitaxel 175 mg/m2 IV on day 1 x 8 cycles plus Doxil 30 mg/m2 IV every other cycle on day 1 x 8 cycles
id
OG002
title
Grade 3 and Above on Carbo/Taxol/Doxil
description
Topotecan 1.25 mg/m2/dIV days 1-3 plus Carboplatin AUC 5 IV on day 3 plus x 4 cycles followed by Carboplatin AUC 6 IV on day 1 plus Paclitaxel 175 mg/m2 IV on day 1 x 4 cycles
id
OG003
title
Grade 3 and Above on Carbo/Topotecan - Carbo/Taxol
description
Gemcitabine 1000 mg/m2/dIV on days 1 and 8 plus Carboplatin AUC 6 IV on day 8 plus x 4 cycles followed by Carboplatin AUC 6 IV on day 1 plus Paclitaxel 175 mg/m2 IV on day 1 x 4 cycles
id
OG004
title
Grade 3 and Above on Carbo/Gemcitabine - Carbo/Taxol

param Type

COUNT_OF_PARTICIPANTS

population Description

Eligible and treated participants

reporting Status

POSTED

time Frame

Up to 9 years

title

Number of Participants With Observed Adverse Effects (Grade 3 and Above) Assessed by Common Toxicity Criteria Version 2.0

type

SECONDARY

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice